165 related articles for article (PubMed ID: 33618175)
1. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
3. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 1
Liu J; Wen Y; Gao L; Gao L; He F; Zhou J; Wang J; Dai R; Chen X; Kang D; Hu L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):72-84. PubMed ID: 31682465
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
Harras MF; Sabour R
Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.
Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099
[TBL] [Abstract][Full Text] [Related]
8. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
9. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4.
Chen X; Li H; Lin Q; Dai S; Qu L; Guo M; Zhang L; Liao J; Wei H; Xu G; Jiang L; Chen Y
Eur J Med Chem; 2024 Mar; 268():116281. PubMed ID: 38432058
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
13. ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma.
Futami T; Okada H; Kihara R; Kawase T; Nakayama A; Suzuki T; Kameda M; Shindoh N; Terasaka T; Hirano M; Kuromitsu S
Mol Cancer Ther; 2017 Jan; 16(1):68-75. PubMed ID: 27837028
[TBL] [Abstract][Full Text] [Related]
14. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors.
AbdElhameid MK; Labib MB; Negmeldin AT; Al-Shorbagy M; Mohammed MR
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1472-1493. PubMed ID: 30191744
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
Liu J; Peng X; Dai Y; Zhang W; Ren S; Ai J; Geng M; Li Y
Org Biomol Chem; 2015 Jul; 13(28):7643-54. PubMed ID: 26080733
[TBL] [Abstract][Full Text] [Related]
18. Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition.
Schmidt B; Wei L; DePeralta DK; Hoshida Y; Tan PS; Sun X; Sventek JP; Lanuti M; Tanabe KK; Fuchs BC
Int J Cancer; 2016 Mar; 138(6):1494-505. PubMed ID: 26481559
[TBL] [Abstract][Full Text] [Related]
19. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.
Cui J; Peng X; Gao D; Dai Y; Ai J; Li Y
Bioorg Med Chem Lett; 2017 Aug; 27(16):3782-3786. PubMed ID: 28687204
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
